{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T09:27:51Z","timestamp":1714987671082},"reference-count":119,"publisher":"Elsevier","isbn-type":[{"value":"9780128018996","type":"print"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1016\/b978-0-12-801899-6.00022-x","type":"book-chapter","created":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T20:23:03Z","timestamp":1449865383000},"page":"447-465","source":"Crossref","is-referenced-by-count":0,"title":["Histone Posttranslational Modifications and Chromatin Remodelers in Prostate Cancer"],"prefix":"10.1016","author":[{"given":"Filipa Quintela","family":"Vieira","sequence":"first","affiliation":[]},{"given":"Diogo","family":"Almeida-Rios","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Gra\u00e7a","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/B978-0-12-801899-6.00022-X_bib2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2014","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/B978-0-12-801899-6.00022-X_bib3","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/B978-0-12-801899-6.00022-X_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5812\/ircmj.6499","article-title":"Prostate cancer: current treatment and prevention strategies","volume":"15","author":"Chen","year":"2013","journal-title":"Iran Red Crescent Med J"},{"key":"10.1016\/B978-0-12-801899-6.00022-X_bib6","series-title":"Prostate cancer","author":"Ramon","year":"2007"},{"issue":"26","key":"10.1016\/B978-0-12-801899-6.00022-X_bib7","doi-asserted-by":"crossref","first-page":"23617","DOI":"10.1074\/jbc.M303423200","article-title":"Covalent histone modifications underlie the developmental regulation of insulin gene transcription in pancreatic beta cells","volume":"278","author":"Chakrabarti","year":"2003","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/B978-0-12-801899-6.00022-X_bib8","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1158\/1055-9965.EPI-10-0555","article-title":"Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development","volume":"19","author":"Bianco-Miotto","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/B978-0-12-801899-6.00022-X_bib9","doi-asserted-by":"crossref","first-page":"e4687","DOI":"10.1371\/journal.pone.0004687","article-title":"Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis","volume":"4","author":"Ke","year":"2009","journal-title":"PLoS One"},{"issue":"7046","key":"10.1016\/B978-0-12-801899-6.00022-X_bib10","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nature03672","article-title":"Global histone modification patterns predict risk of prostate cancer recurrence","volume":"435","author":"Seligson","year":"2005","journal-title":"Nature"},{"issue":"Spec No. 1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib11","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1093\/hmg\/ddm021","article-title":"Cancer genetics of epigenetic genes","volume":"16","author":"Miremadi","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jcp.21678","article-title":"Epigenetic control","volume":"219","author":"Delcuve","year":"2009","journal-title":"J Cell Physiol"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in cancer","volume":"31","author":"Sharma","year":"2010","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/B978-0-12-801899-6.00022-X_bib14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nm.2305","article-title":"Cancer epigenetics reaches mainstream oncology","volume":"17","author":"Rodriguez-Paredes","year":"2011","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.gde.2012.02.008","article-title":"Cancer epigenomics: beyond genomics","volume":"22","author":"Sandoval","year":"2012","journal-title":"Curr Opin Genet Dev"},{"issue":"11","key":"10.1016\/B978-0-12-801899-6.00022-X_bib16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N Engl J Med"},{"issue":"5532","key":"10.1016\/B978-0-12-801899-6.00022-X_bib17","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","article-title":"Translating the histone code","volume":"293","author":"Jenuwein","year":"2001","journal-title":"Science"},{"issue":"7","key":"10.1016\/B978-0-12-801899-6.00022-X_bib18","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMra1112635","article-title":"Targeting epigenetic readers in cancer","volume":"367","author":"Dawson","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/B978-0-12-801899-6.00022-X_bib19","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/nsmb851","article-title":"Regulated nucleosome mobility and the histone code","volume":"11","author":"Cosgrove","year":"2004","journal-title":"Nat Struct Mol Biol"},{"issue":"19","key":"10.1016\/B978-0-12-801899-6.00022-X_bib20","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1101\/gad.1232504","article-title":"Epigenetics and cancer","volume":"18","author":"Lund","year":"2004","journal-title":"Genes Dev"},{"issue":"4","key":"10.1016\/B978-0-12-801899-6.00022-X_bib21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/B978-0-12-801899-6.00022-X_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nsmb.2470","article-title":"Regulation of nucleosome dynamics by histone modifications","volume":"20","author":"Zentner","year":"2013","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"10.1016\/B978-0-12-801899-6.00022-X_bib23","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/B978-0-12-801899-6.00022-X_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins","volume":"363","author":"Glozak","year":"2005","journal-title":"Gene"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0959-437X(96)80048-7","article-title":"Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation","volume":"6","author":"Brownell","year":"1996","journal-title":"Curr Opin Genet Dev"},{"issue":"7","key":"10.1016\/B978-0-12-801899-6.00022-X_bib26","doi-asserted-by":"crossref","first-page":"a018762","DOI":"10.1101\/cshperspect.a018762","article-title":"Writers and readers of histone acetylation: structure, mechanism, and inhibition","volume":"6","author":"Marmorstein","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"Pt 3","key":"10.1016\/B978-0-12-801899-6.00022-X_bib27","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","article-title":"Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis","volume":"338","author":"Gregoretti","year":"2004","journal-title":"J Mol Biol"},{"issue":"18","key":"10.1016\/B978-0-12-801899-6.00022-X_bib29","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1101\/gad.927301","article-title":"Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails","volume":"15","author":"Zhang","year":"2001","journal-title":"Genes Dev"},{"issue":"7","key":"10.1016\/B978-0-12-801899-6.00022-X_bib30","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","article-title":"Histone demethylation mediated by the nuclear amine oxidase homolog LSD1","volume":"119","author":"Shi","year":"2004","journal-title":"Cell"},{"issue":"5849","key":"10.1016\/B978-0-12-801899-6.00022-X_bib31","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1126\/science.1145801","article-title":"JMJD6 is a histone arginine demethylase","volume":"318","author":"Chang","year":"2007","journal-title":"Science"},{"issue":"8","key":"10.1016\/B978-0-12-801899-6.00022-X_bib32","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/rcm.1421","article-title":"A mass spectrometry based method for distinguishing between symmetrically and asymmetrically dimethylated arginine residues","volume":"18","author":"Brame","year":"2004","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"13","key":"10.1016\/B978-0-12-801899-6.00022-X_bib33","doi-asserted-by":"crossref","first-page":"8476","DOI":"10.1074\/jbc.M511093200","article-title":"Histone H3 lysine 9 methyltransferase G9a is a transcriptional coactivator for nuclear receptors","volume":"281","author":"Lee","year":"2006","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib34","first-page":"75","article-title":"Histone lysine methylation and demethylation pathways in cancer","volume":"1815","author":"Varier","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"10.1016\/B978-0-12-801899-6.00022-X_bib35","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.febslet.2010.11.010","article-title":"Histone arginine methylation","volume":"585","author":"Di Lorenzo","year":"2011","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1042\/BSR20080176","article-title":"Histone arginine methylations: their roles in chromatin dynamics and transcriptional regulation","volume":"29","author":"Litt","year":"2009","journal-title":"Biosci Rep"},{"issue":"10","key":"10.1016\/B978-0-12-801899-6.00022-X_bib37","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/cmdc.200900301","article-title":"The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors","volume":"4","author":"Spannhoff","year":"2009","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/hdy.2010.49","article-title":"Epigenetic regulation of development by histone lysine methylation","volume":"105","author":"Dambacher","year":"2010","journal-title":"Heredity"},{"issue":"9","key":"10.1016\/B978-0-12-801899-6.00022-X_bib39","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1101\/gad.1652908","article-title":"Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease","volume":"22","author":"Cloos","year":"2008","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bbagrm.2008.06.005","article-title":"Chemical mechanisms of histone lysine and arginine modifications","volume":"1789","author":"Smith","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/B978-0-12-801899-6.00022-X_bib41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrm3327","article-title":"Molecular mechanisms and potential functions of histone demethylases","volume":"13","author":"Kooistra","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"10.1016\/B978-0-12-801899-6.00022-X_bib42","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1158\/0008-5472.CAN-13-2485","article-title":"p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis","volume":"74","author":"Zhong","year":"2014","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/B978-0-12-801899-6.00022-X_bib43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1006\/bbrc.2001.5639","article-title":"Histone deacetylase and DNA methyltransferase in human prostate cancer","volume":"287","author":"Patra","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/B978-0-12-801899-6.00022-X_bib44","first-page":"273","article-title":"Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells","volume":"48","author":"Waltregny","year":"2004","journal-title":"Eur J Histochem"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pros.20022","article-title":"Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer","volume":"59","author":"Halkidou","year":"2004","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/B978-0-12-801899-6.00022-X_bib46","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/B978-0-12-801899-6.00022-X_bib47","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1517\/14728221003796609","article-title":"Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin\u2019s lymphoma","volume":"14","author":"Adams","year":"2010","journal-title":"Expert Opin Ther Targets"},{"issue":"9","key":"10.1016\/B978-0-12-801899-6.00022-X_bib48","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s13238-013-3054-5","article-title":"Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics","volume":"4","author":"Liu","year":"2013","journal-title":"Protein Cell"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib49","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajpath.2014.09.014","article-title":"Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria","volume":"185","author":"Di Sante","year":"2015","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/B978-0-12-801899-6.00022-X_bib50","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.18632\/oncotarget.1237","article-title":"Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer","volume":"4","author":"Baptista","year":"2013","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/B978-0-12-801899-6.00022-X_bib51","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-13-2699","article-title":"Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence","volume":"74","author":"Long","year":"2014","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/B978-0-12-801899-6.00022-X_bib52","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1210\/me.2006-0467","article-title":"Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor","volume":"21","author":"Dai","year":"2007","journal-title":"Mol Endocrinol"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/pros.21038","article-title":"Global levels of histone modifications predict prostate cancer recurrence","volume":"70","author":"Ellinger","year":"2010","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/B978-0-12-801899-6.00022-X_bib54","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2353\/ajpath.2009.080874","article-title":"Global levels of histone modifications predict prognosis in different cancers","volume":"174","author":"Seligson","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/B978-0-12-801899-6.00022-X_bib55","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/1471-2164-11-669","article-title":"Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells","volume":"11","author":"Ke","year":"2010","journal-title":"BMC Genomics"},{"issue":"6","key":"10.1016\/B978-0-12-801899-6.00022-X_bib56","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/pros.21112","article-title":"Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines","volume":"70","author":"Karanikolas","year":"2010","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/B978-0-12-801899-6.00022-X_bib57","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4161\/cbt.6.9.4542","article-title":"Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer","volume":"6","author":"Hoffmann","year":"2007","journal-title":"Cancer Biol Ther"},{"issue":"6907","key":"10.1016\/B978-0-12-801899-6.00022-X_bib58","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"issue":"Spec No 1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib59","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1093\/hmg\/ddi106","article-title":"Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes","volume":"14","author":"Gibbons","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/B978-0-12-801899-6.00022-X_bib60","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.eururo.2011.06.035","article-title":"Epigenetics in prostate cancer: biologic and clinical relevance","volume":"60","author":"Jeronimo","year":"2011","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/B978-0-12-801899-6.00022-X_bib61","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13238-013-2093-2","article-title":"EZH2, an epigenetic driver of prostate cancer","volume":"4","author":"Yang","year":"2013","journal-title":"Protein Cell"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib62","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"Bachmann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/B978-0-12-801899-6.00022-X_bib63","doi-asserted-by":"crossref","first-page":"10657","DOI":"10.1158\/0008-5472.CAN-07-2498","article-title":"A polycomb repression signature in metastatic prostate cancer predicts cancer outcome","volume":"67","author":"Yu","year":"2007","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib64","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s13148-011-0041-7","article-title":"Epigenetic regulation of prostate cancer","volume":"2","author":"Chin","year":"2011","journal-title":"Clin Epigenetics"},{"issue":"4","key":"10.1016\/B978-0-12-801899-6.00022-X_bib65","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/epi.10.31","article-title":"Histone modifications and chromatin organization in prostate cancer","volume":"2","author":"Chen","year":"2010","journal-title":"Epigenomics"},{"issue":"4","key":"10.1016\/B978-0-12-801899-6.00022-X_bib66","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1371\/journal.pone.0000386","article-title":"Genome-wide studies of histone demethylation catalysed by the fission yeast homologues of mammalian LSD1","volume":"2","author":"Opel","year":"2007","journal-title":"PLoS One"},{"issue":"7057","key":"10.1016\/B978-0-12-801899-6.00022-X_bib67","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature04020","article-title":"LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription","volume":"437","author":"Metzger","year":"2005","journal-title":"Nature"},{"issue":"23","key":"10.1016\/B978-0-12-801899-6.00022-X_bib68","doi-asserted-by":"crossref","first-page":"11341","DOI":"10.1158\/0008-5472.CAN-06-1570","article-title":"Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence","volume":"66","author":"Kahl","year":"2006","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/B978-0-12-801899-6.00022-X_bib69","doi-asserted-by":"crossref","first-page":"15471","DOI":"10.1074\/jbc.M701023200","article-title":"The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners","volume":"282","author":"Scoumanne","year":"2007","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/B978-0-12-801899-6.00022-X_bib70","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ijc.25349","article-title":"Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers","volume":"128","author":"Hayami","year":"2011","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/B978-0-12-801899-6.00022-X_bib71","doi-asserted-by":"crossref","first-page":"558","DOI":"10.2174\/1568009611313050007","article-title":"Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention","volume":"13","author":"Tian","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"issue":"7","key":"10.1016\/B978-0-12-801899-6.00022-X_bib72","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc2876","article-title":"Covalent histone modifications\u2013miswritten, misinterpreted and mis-erased in human cancers","volume":"10","author":"Chi","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib73","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrurol.2012.225","article-title":"Risk stratification in prostate cancer screening","volume":"10","author":"Roobol","year":"2012","journal-title":"Nat Rev Urol"},{"key":"10.1016\/B978-0-12-801899-6.00022-X_bib74","series-title":"Anatomy of the prostate gland and surgical pathology of prostate cancer","first-page":"1","author":"Hammerich","year":"2009"},{"issue":"4","key":"10.1016\/B978-0-12-801899-6.00022-X_bib75","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc2351","article-title":"Prostate-specific antigen and prostate cancer: prediction, detection and monitoring","volume":"8","author":"Lilja","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/B978-0-12-801899-6.00022-X_bib76","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1371\/journal.pmed.0050114","article-title":"Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis","volume":"5","author":"Chan","year":"2008","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib77","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/aja.2009.81","article-title":"Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy","volume":"12","author":"Zhou","year":"2010","journal-title":"Asian J Androl"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib78","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/07357907.2011.636117","article-title":"Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer","volume":"30","author":"Ellinger","year":"2012","journal-title":"Cancer Invest"},{"issue":"19","key":"10.1016\/B978-0-12-801899-6.00022-X_bib79","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.cca.2010.05.040","article-title":"Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease","volume":"411","author":"Deligezer","year":"2010","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib80","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2490-12-5","article-title":"Alterations of global histone H4K20 methylation during prostate carcinogenesis","volume":"12","author":"Behbahani","year":"2012","journal-title":"BMC Urol"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib81","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/ERC-13-0375","article-title":"Deregulated expression of selected histone methylases and demethylases in prostate carcinoma","volume":"21","author":"Vieira","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib82","first-page":"123","article-title":"EZH2 expression in human prostate cancer and its clinicopathologic significance","volume":"16","author":"Li","year":"2010","journal-title":"Zhonghua Nan Ke Xue"},{"issue":"9","key":"10.1016\/B978-0-12-801899-6.00022-X_bib83","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.humpath.2013.01.022","article-title":"Overexpression of the chromatin remodeler death-domain\u2013associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence","volume":"44","author":"Tsourlakis","year":"2013","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/B978-0-12-801899-6.00022-X_bib84","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.molonc.2012.07.003","article-title":"Histone deacetylases and cancer","volume":"6","author":"Barneda-Zahonero","year":"2012","journal-title":"Mol Oncol"},{"key":"10.1016\/B978-0-12-801899-6.00022-X_bib85","unstructured":"Kozikowski A, Butler K, Kalin J. Hdac inhibitors and therapeutic methods using the same. WO Patent 2011011186; 2011."},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib86","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/excr.2000.5080","article-title":"The human histone deacetylase family","volume":"262","author":"Gray","year":"2001","journal-title":"Exp Cell Res"},{"issue":"5942","key":"10.1016\/B978-0-12-801899-6.00022-X_bib87","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"issue":"12","key":"10.1016\/B978-0-12-801899-6.00022-X_bib88","first-page":"2981","article-title":"Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells","volume":"59","author":"Huang","year":"1999","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/B978-0-12-801899-6.00022-X_bib89","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/pros.20587","article-title":"Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in\u00a0vitro and in\u00a0vivo","volume":"67","author":"Shabbeer","year":"2007","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib90","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2011.07.015","article-title":"Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells","volume":"311","author":"Chou","year":"2011","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib91","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ijc.21824","article-title":"SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis","volume":"119","author":"Lakshmikanthan","year":"2006","journal-title":"Int J Cancer"},{"issue":"18","key":"10.1016\/B978-0-12-801899-6.00022-X_bib92","first-page":"5165","article-title":"Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in\u00a0vitro and in\u00a0vivo","volume":"60","author":"Butler","year":"2000","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib93","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2004.12.088","article-title":"Modulation of radiation response by histone deacetylase inhibition","volume":"62","author":"Chinnaiyan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/B978-0-12-801899-6.00022-X_bib94","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1158\/1535-7163.MCT-07-0221","article-title":"Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in\u00a0vitro","volume":"6","author":"Sonnemann","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib95","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.freeradbiomed.2010.11.011","article-title":"Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells","volume":"50","author":"Pettazzoni","year":"2011","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib96","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/pros.21051","article-title":"Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Pur\u03b1-mediated decrease in androgen receptor levels","volume":"70","author":"Liu","year":"2010","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/B978-0-12-801899-6.00022-X_bib97","doi-asserted-by":"crossref","first-page":"e74253","DOI":"10.1371\/journal.pone.0074253","article-title":"Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate Cancer cells","volume":"8","author":"Xiao","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/B978-0-12-801899-6.00022-X_bib98","first-page":"711","article-title":"Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models","volume":"40","author":"Sante","year":"2012","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib99","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.urolonc.2007.01.020","article-title":"Depsipeptide (FK228) inhibits growth of human prostate cancer cells","volume":"26","author":"Lai","year":"2008","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/B978-0-12-801899-6.00022-X_bib100","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.urology.2007.03.052","article-title":"Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel","volume":"70","author":"Zhang","year":"2007","journal-title":"Urology"},{"issue":"11","key":"10.1016\/B978-0-12-801899-6.00022-X_bib101","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/pros.20611","article-title":"Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models","volume":"67","author":"Qian","year":"2007","journal-title":"Prostate"},{"issue":"18","key":"10.1016\/B978-0-12-801899-6.00022-X_bib102","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1158\/1078-0432.CCR-04-0537","article-title":"Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation","volume":"10","author":"Camphausen","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib103","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/mol.110.067702","article-title":"Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases","volume":"79","author":"Huang","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"23","key":"10.1016\/B978-0-12-801899-6.00022-X_bib104","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1002\/cncr.24597","article-title":"Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)","volume":"115","author":"Bradley","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/B978-0-12-801899-6.00022-X_bib105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00280-013-2224-8","article-title":"A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer","volume":"72","author":"Rathkopf","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib106","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/annonc\/mdp270","article-title":"Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)","volume":"21","author":"Molife","year":"2010","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/B978-0-12-801899-6.00022-X_bib107","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/sj.bjc.6605293","article-title":"Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker","volume":"101","author":"Munster","year":"2009","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib108","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-010-1289-x","article-title":"A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer","volume":"66","author":"Rathkopf","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1016\/B978-0-12-801899-6.00022-X_bib109","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/carcin\/bgs312","article-title":"Curcumin inhibits prostate cancer metastasis in\u00a0vivo by targeting the inflammatory cytokines CXCL1 and -2","volume":"33","author":"Killian","year":"2012","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/B978-0-12-801899-6.00022-X_bib110","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1208\/s12248-011-9300-y","article-title":"Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells","volume":"13","author":"Shu","year":"2011","journal-title":"AAPS J"},{"issue":"9","key":"10.1016\/B978-0-12-801899-6.00022-X_bib111","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1158\/1535-7163.MCT-11-0182","article-title":"Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines","volume":"10","author":"Santer","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"39","key":"10.1016\/B978-0-12-801899-6.00022-X_bib112","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1038\/onc.2011.601","article-title":"Epigenetic cancer therapy: rationales, targets and drugs","volume":"31","author":"Rius","year":"2012","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/B978-0-12-801899-6.00022-X_bib113","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-09-0013","article-title":"DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation","volume":"8","author":"Miranda","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/B978-0-12-801899-6.00022-X_bib114","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1476-4598-10-40","article-title":"Pharmacologic disruption of polycomb repressive complex 2 inhibits tumorigenicity and tumor progression in prostate cancer","volume":"10","author":"Crea","year":"2011","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/B978-0-12-801899-6.00022-X_bib115","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.3892\/or.2013.2635","article-title":"Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells","volume":"30","author":"Lee","year":"2013","journal-title":"Oncol Rep"},{"issue":"11","key":"10.1016\/B978-0-12-801899-6.00022-X_bib116","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/ijc.27555","article-title":"Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor","volume":"131","author":"Willmann","year":"2012","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/B978-0-12-801899-6.00022-X_bib117","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/MCB.01020-07","article-title":"Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression","volume":"28","author":"Yang","year":"2008","journal-title":"Mol Cell Biol"},{"issue":"12","key":"10.1016\/B978-0-12-801899-6.00022-X_bib118","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.18632\/oncotarget.1572","article-title":"Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer","volume":"4","author":"Wyce","year":"2013","journal-title":"Oncotarget"},{"issue":"7504","key":"10.1016\/B978-0-12-801899-6.00022-X_bib119","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"}],"container-title":["Epigenetic Biomarkers and Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B978012801899600022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B978012801899600022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T14:22:54Z","timestamp":1599920574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B978012801899600022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9780128018996"],"references-count":119,"URL":"https:\/\/doi.org\/10.1016\/b978-0-12-801899-6.00022-x","relation":{},"subject":[],"published":{"date-parts":[[2016]]}}}